Prosecution Insights
Last updated: May 29, 2026

Shanghai Epiprobe Biotechnology Co. Ltd.

4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready

Portfolio Summary

4
Total Pending OAs
1
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (50%)
2
Easy (50%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (50%)
§112 only2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DAUNER, JOSEPH G 1 56.8% +34.8%
HANEY, AMANDA MARIE 1 36.6% +44.1%
BUCHANAN, BAILEY CHEYENNE 1 50.0% +46.7%
GIAMMONA, FRANCESCA FILIPPA 1 35.7% +53.3%

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17309902 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP6 BUCHANAN, BAILEY CHEYENNE 49d overdue
17250457 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP1 GIAMMONA, FRANCESCA FILIPPA 30d overdue
17594792 METHYLATION-BASED MODIFIED TUMOR MARKER STAMP-EP8 AND APPLICATION THEREOF DAUNER, JOSEPH G 8d
17309901 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP4 HANEY, AMANDA MARIE 22d

Top Art Units

Art UnitApps
1682 3
1681 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17594792 METHYLATION-BASED MODIFIED TUMOR MARKER STAMP-EP8 AND APPLICATION THEREOF DAUNER, JOSEPH G 1682 §112 Final Rejection 8d Pending May 20, 2022
17309901 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP4 HANEY, AMANDA MARIE 1682 §112 Final Rejection 22d Pending Feb 14, 2022
17309902 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP6 BUCHANAN, BAILEY CHEYENNE 1682 §103 Non-Final OA 49d overdue Pending Feb 14, 2022
17250457 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP1 GIAMMONA, FRANCESCA FILIPPA 1681 §103 Final Rejection 30d overdue Pending Sep 13, 2021

Managing Shanghai Epiprobe Biotechnology Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month